O
OrbiMed Portfolio holdings
AUM
$5.4B
Turnover
40.13%
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+30.69%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.46B
AUM Growth
+$453M
(+9%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-5.72%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
132
New
22
Increased
22
Reduced
29
Closed
18
Avg Time Held Equity + Options
2.6
years
Top 10 Avg Time Held Equity + Options
0.9
years
Top 20 Avg Time Held Equity + Options
1.3
years
Avg Time Held Equity only
2.6
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ArriVent BioPharma
AVBP
|
+$61.1M |
| 2 |
Cytokinetics
CYTK
|
+$52.8M |
| 3 |
Esperion Therapeutics
ESPR
|
+$33.3M |
| 4 |
Merck
MRK
|
+$32.2M |
| 5 |
Q32 Bio
QTTB
|
+$31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RayzeBio, Inc. Common Stock
RYZB
|
+$147M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$93.5M |
| 3 |
United Therapeutics
UTHR
|
+$84.9M |
| 4 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$71.7M |
| 5 |
SpringWorks Therapeutics
SWTX
|
+$69.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.1% |
| 2 | Miscellaneous | 0.9% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Invivyd
IVVD
$182M
| $11.9M | 0.22% |
2,690,300
-1,437,265
| -35% | -$5.94M |
2021 Q3
10 quarters
|
|
77
PMV Pharmaceuticals
PMVP
$69M
| $11M | 0.2% |
6,475,291
| – | – |
2020 Q3
14 quarters
|
|
78
DELISTED
Ventyx Biosciences
VTYX
| $10.3M | 0.19% |
+1,870,456
| New | +$8.55M |
2024 Q1
0 quarters
|
|
79
Fate Therapeutics
FATE
$230M
| $9.95M | 0.18% |
1,355,352
+827,272
| +157% | +$5.12M |
2023 Q4
1 quarter
|
|
80
X4 Pharmaceuticals
XFOR
$244M
| $9.92M | 0.18% |
237,784
| – | – |
2017 Q4
25 quarters
|
|
81
DELISTED
Exact Sciences
EXAS
| $9.7M | 0.18% |
+140,400
| New | +$8.88M |
2024 Q1
0 quarters
|
|
82
Cullinan Oncology
CGEM
$877M
| $8.82M | 0.16% |
517,606
-27,242
| -5% | -$421K |
2021 Q1
12 quarters
|
|
83
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $8.82M | 0.16% |
+150,000
| New | +$9.56M |
2024 Q1
0 quarters
|
|
84
Nkarta
NKTX
$149M
| $8.65M | 0.16% |
+800,000
| New | +$8.32M |
2024 Q1
0 quarters
|
|
85
Lexicon Pharmaceuticals
LXRX
$716M
| $8.5M | 0.16% |
+3,542,000
| New | +$7.61M |
2024 Q1
0 quarters
|
|
86
10x Genomics
TXG
$9.44B
| $8.45M | 0.15% |
225,200
+185,400
| +466% | +$8.15M |
2023 Q4
1 quarter
|
|
87
DELISTED
Turnstone Biologics
TSBX
| $8.12M | 0.15% |
3,099,265
| – | – |
2023 Q3
2 quarters
|
|
88
Perspective Therapeutics
CATX
$257M
| $7.74M | 0.14% |
+650,580
| New | +$5.55M |
2024 Q1
0 quarters
|
|
89
CytomX Therapeutics
CTMX
$482M
| $7.73M | 0.14% |
+3,544,578
| New | +$6.54M |
2024 Q1
0 quarters
|
|
90
DELISTED
Amicus Therapeutics
FOLD
| $6.72M | 0.12% |
570,300
-235,700
| -29% | -$3.01M |
2023 Q4
1 quarter
|
|
91
Krystal Biotech
KRYS
$9.71B
| $6.61M | 0.12% |
37,166
-66,534
| -64% | -$9.24M |
2023 Q4
1 quarter
|
|
92
Vir Biotechnology
VIR
$1.78B
| $6.48M | 0.12% |
640,000
+539,000
| +534% | +$5.49M |
2023 Q4
1 quarter
|
|
93
Apollomics
APLM
$63.5M
| $6.42M | 0.12% |
85,655
| – | – |
2023 Q1
4 quarters
|
|
94
InspireMD
NSPR
$23.2M
| $5.06M | 0.09% |
2,133,405
| – | – |
2023 Q2
3 quarters
|
|
95
ImageneBio Inc
IMA
$47.6M
| $5.03M | 0.09% |
294,947
| – | – |
2021 Q1
12 quarters
|
|
96
DELISTED
Elevation Oncology
ELEV
| $4.83M | 0.09% |
941,275
-558,725
| -37% | -$1.81M |
2023 Q2
3 quarters
|
|
97
Progyny
PGNY
$2.13B
| $4.32M | 0.08% |
+113,300
| New | +$4.28M |
2024 Q1
0 quarters
|
|
98
CALL
SI-BONE Inc
SIBN
$878M
| $4.09M | 0.08% |
+250,000
| New | +$4.71M |
2024 Q1
0 quarters
|
|
99
Oric Pharmaceuticals
ORIC
$1.2B
| $3.95M | 0.07% |
287,100
-235,868
| -45% | -$2.8M |
2020 Q2
15 quarters
|
|
100
Milestone Pharmaceuticals
MIST
$95.6M
| $3.58M | 0.07% |
+2,000,000
| New | +$3.25M |
2024 Q1
0 quarters
|
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q1 2024 Portfolio in Review
As of Q1 2024, OrbiMed held 132 positions worth $5.46B, up 9% from $5.01B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed withdrew a net $312M in Q1 2024, closing 18 positions and reducing 29 holdings. Its most notable exit was RayzeBio, Inc. Common Stock, an estimated $147M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, OrbiMed opened a new position in ArriVent BioPharma worth $54.1M.
- OrbiMed's largest Q1 2024 buy was ArriVent BioPharma: 3,027,328 shares worth $54.1M.
- OrbiMed added most to Merck in Q1 2024, an estimated $32.2M increase.
- OrbiMed's biggest Q1 2024 reduction was SpringWorks Therapeutics, cutting an estimated $69.9M.
- OrbiMed fully exited RayzeBio, Inc. Common Stock in Q1 2024, selling an estimated $147M.
- OrbiMed's ten largest holdings make up 39% of its $5.46B portfolio in Q1 2024.
- OrbiMed opened 22 new positions and closed 18 in Q1 2024.
- OrbiMed's portfolio value rose 9% quarter-over-quarter to $5.46B.
Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.